Advertisement
U.S. markets open in 3 hours 18 minutes
  • S&P Futures

    5,304.25
    -4.00 (-0.08%)
     
  • Dow Futures

    40,141.00
    -3.00 (-0.01%)
     
  • Nasdaq Futures

    18,482.75
    -21.00 (-0.11%)
     
  • Russell 2000 Futures

    2,135.50
    -2.90 (-0.14%)
     
  • Crude Oil

    81.93
    +0.58 (+0.71%)
     
  • Gold

    2,218.20
    +5.50 (+0.25%)
     
  • Silver

    24.57
    -0.19 (-0.76%)
     
  • EUR/USD

    1.0783
    -0.0047 (-0.43%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2605
    -0.0033 (-0.26%)
     
  • USD/JPY

    151.4460
    +0.2000 (+0.13%)
     
  • Bitcoin USD

    70,626.32
    +606.93 (+0.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,972.54
    +40.56 (+0.51%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Bristol-Myers says Starboard nominated five directors, bought shares

BOSTON, Feb 20 (Reuters) - Bristol-Myers Squibb Co. said on Wednesday that activist hedge fund Starboard Value LP wants to add five directors to its board and bought one million shares after the pharmaceutical company said it plans to buy biotech company Celgene Corp.

"Starboard Value sent Bristol-Myers Squibb a notice of nomination in connection with Bristol-Myers Squibb's 2019 Annual Meeting of Stockholders," the company said in a regulatory filing on Wednesday, adding that the hedge fund proposed five directors, including the firm's co-founder, Jeffrey Smith. The company did not say when Starboard sent its notice.

(Reporting by Svea Herbst-Bayliss and Greg Roumeliotis)

Advertisement